Tubulis

Munich, Germany

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

$400.6M raised

Oct 2025

Series C

Top Investors

Wellington ManagementHTGF (High-Tech Gruenderfonds)Seventure PartnersEQT Life SciencesAndera Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Tubulis raised?

Tubulis has raised $400.6M in total funding. The most recent round was Series C. The last funding was announced in October 2025.

Who are Tubulis's investors?

Tubulis's investors include Wellington Management, HTGF (High-Tech Gruenderfonds), Seventure Partners, EQT Life Sciences, Andera Partners.

Where is Tubulis headquartered?

Tubulis is headquartered in Munich, Germany.

What does Tubulis do?

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

What stage is Tubulis at?

Tubulis is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 15, 2025.

MLA

"Tubulis — Funding & Investors." VCBacked, October 15, 2025, https://www.vcbacked.co/company/tubulis. Accessed June 3, 2026.

APA

VCBacked. (2025). Tubulis — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/tubulis

Wikipedia (cite web)

{{cite web |title=Tubulis — Funding & Investors |url=https://www.vcbacked.co/company/tubulis |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 15, 2025.